Adynxx, Inc. (ADYX)
|Net Income (ttm)||-8.73M|
|Trading Day||July 30|
|Day's Range||0.1000 - 0.1000|
|52-Week Range||0.0300 - 1.1800|
There are no news available yet.
Adynxx, Inc., a clinical stage biopharmaceutical company, focuses on the development and marketing of transcription factor decoy technologies for the treatment of pain and inflammatory diseases. It is involved in the development of AYX platform of transcription factor decoys, including brivoligide, which is in Phase II clinical development for the reduction of postoperative pain; and AYX2, a pre-clinical candidate intended for the treatment of focal chronic pain. The company was founded in 2007 and is headquartered in San Francisco, California.
|Stock Exchange |
|Ticker Symbol |
In 2018, Adynxx's revenue was $2.22 million, an increase of 9.76% compared to the previous year's $2.02 million. Losses were -$8.42 million, -67.26% less than in 2017.